NON RADIOACTIVE METHOD TO MEASURE ORGAN BLOOD FLOW

描述：（改编自申请人的摘要）： 拟议的研究是验证一种测量局部器官血液的新方法 使用中子测定的非放射性、稳定标记的微球的流动 活化（NA）分析。该建议基于以下假设： 引入生物基质中的稳定标记的研究产品可以 使用NA准确快速测定。这项技术将提供一个 降低低放射性核素产生的成本效益高的方法 生物医学研究产生的废物。长期目标是发展 基于NA技术的其他研究产品，可用于 目前的非放射性方法是劳动密集型的， 有效拟议项目的第一阶段是内部阿尔法测试， 直接比较稳定标记的微球与放射性标记的 在冠状动脉闭塞和再灌注的体内兔模型中的微球。 将使用统计分析评估两种方法之间的一致性， 从而支持工作假设并证明可行性。相 我还将提供自动激活的重要设计参数， 在第二阶段建设的计数系统。该自动化系统将 能够分析商业所需的大量样品， 操作 拟议商业应用：不可用

DESCRIPTION: (Adapted from applicant's abstract): The specific aim of the proposed study is to validate a new method of measuring regional organ blood flow using non-radioactive, stable-labeled microspheres assayed by neutron activation (NA) analysis. The proposal is based on the hypothesis that stable-labeled research products introduced into a biological matrix can be accurately and rapidly assayed using NA. This technology will provide a cost-effective method for reducing the production of low-level radioactive waste generated from biomedical research. The long-term goal is to develop additional research products based on the NA technology, which could be used in applications where current non-radioactive methods are labor-intensive and less effective. Phase I of the proposed project is an in-house alpha test which will directly compare stable-labeled microspheres to a co-injection of radiolabeled microspheres in an in vivo rabbit model of coronary occlusion and reperfusion. Statistical analysis will be used to assess agreement between the two methods, thereby supporting the working hypothesis and demonstrating feasibility. Phase I will also provide important design parameters for an automated activation and counting system to be constructed during Phase II. This automated system will be able to assay the large numbers of samples necessary for commercial operation. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE